A prospective follow-up of two 21/7 cycles followed by two extended regimen 84/7 cycles with contraceptive pills containing ethinyl estradiol and drospirenone

Israel Medical Association Journal

Volumn 12, Issue 7, 2010, Pages 400-405

  Seidman, Daniel S ^a   Yeshaya, Arie ^a   Ber, Amos ^a   Amodai, Ida ^a   Feinstein, Itzhak ^a   Finkel, Israelit ^a   Gordon, Nina ^a   Porat, Noga ^a   Samuel, Dganit ^a   Shiran Makler, Einat ^a   Wolman, Igal ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Combined hormonal contraceptives; Continuous administration; Menorrhagia; Menstrual symptoms; Non bleeding contraceptives; Spotting

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL; ANDROSTANE DERIVATIVE; DROSPIRENONE; ETHINYLESTRADIOL; MINERALOCORTICOID ANTAGONIST; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BLOATING; BODY WEIGHT; BREAKTHROUGH BLEEDING; BREAST TENDERNESS; CONTROLLED STUDY; CUTANEOUS PARAMETERS; DEPRESSION; DOSAGE SCHEDULE COMPARISON; DRUG WITHDRAWAL; DYSMENORRHEA; EDEMA; FEMALE; FOLLOW UP; HORMONAL CONTRACEPTION; HUMAN; IRRITABILITY; MENORRHAGIA; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PREMENSTRUAL SYNDROME; PROSPECTIVE STUDY; PSYCHOLOGICAL GENERAL WELL BEING INDEX; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; SCORING SYSTEM; SIDE EFFECT; UTERINE BLEEDING PATTERN; DRUG ADMINISTRATION; DRUG EFFECTS; MENSTRUATION; MENSTRUATION DISTURBANCES; QUESTIONNAIRE;

ADULT; ALDOSTERONE ANTAGONISTS; ANDROSTENES; CONTRACEPTIVES, ORAL, COMBINED; DRUG ADMINISTRATION SCHEDULE; ETHINYL ESTRADIOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MENSTRUATION; MENSTRUATION DISTURBANCES; PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; MINERALOCORTICOID RECEPTOR ANTAGONISTS; SURVEYS AND QUESTIONNAIRES;

EID: 77955071141     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Clarke AK, Miller SJ. Te debate regarding continuous use of oral contraceptives. Ann Pharmacother 2001; 35: 1480-4.
2. MacGregor A. Migraine associated with menstruation. Funct Neurol 2000; 15: 143-53.
3. Vercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R, Crosignani PG. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 2003; 80: 560-3.
4. Vercellini P, De Giorgi O, Mosconi P, Stellato G, Vicentini G, Crosignani PG. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain afer conservative surgery for symptomatic endometriosis. Fertil Steril 2002; 77: 52-61.
5. Legro RS, Pauli JG, Kunselman AR, et al. Efects of continuous versus cyclical oral contraception: a randomized controlled trial. J Clin Endocrinol Metab 2008; 93: 420-9.
6. Miller L, Notter KM. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Obstet Gynecol 2001; 98: 771-8.
7. Miller L, Hughes J P. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 2003; 101: 653-61.
8. Kwiecien M, Edelman A, Nichols MD, Jensen JT. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception 2003;67: 9-13.
9. Sillem M, Schneidereit R, Heithecker R, Mueck AO. Use of an oral contraceptive containing drospirenone in an extended regimen. Eur J Contrac Reprod Health Care 2003; 8: 162-9.
10. Foidart JM, Sulak PJ, Schellschmidt I, Zimmermann D. Yasmin Extended Regimen Study Group. Te use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days. Contraception 2006; 73: 34-40.
11. Sulak PJ, Kuehl TJ, Cofee A, Willis S. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. Am J Obstet Gynecol 2006; 195: 935-41.
12. Edelman A, Gallo MF, Nichols MD, Jensen JT, Schulz KF, Grimes DA. Continuous versus cyclic use of combined oral contraceptives for contraception: systematic Cochrane review of randomized controlled trials. Hum Reprod 2006; 21: 573-8.
13. Dupuy HJ. Te psychological general well-being (PGWB) index. In: Wenger NK, Mattson ME, Furberg CD, Elinson J, eds. Assessment of Quality of Life in Clinical Trials. New York, NY: Le Jacq Publishing Inc, 1984: 170-83, 353-6.
14. Coutinho EM, Barbosa IC, Zhi-Ping G, Shaaban MM, Aboul-Oyoon M, Aleem AH. Comparative study on intermittent versus continuous use of a contraceptive pill administered by vaginal route. Contraception 1995; 51: 355-8.
15. Anderson FD, Hait H. A multicenter randomized study of an extended cycle oral contraceptive. Contraception 2003; 69: 89-96.
16. Cachrimanidou AC, Hellberg D, Nilssen S, Waldenstrom U, Olssan SE, Sikstorm B. Long interval treatment regimen with a desogestrel-containing oral contraceptive. Contraception 1993; 48: 205-16.
17. Cofee AL, Huehl TJ, Willis S, Sulak PJ. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol 2006; 195: 1311-19.
18. Sabatini R, Orsini G, Cagiano R, Loverro G. Noncontraceptive benefts of two combined oral contraceptives with antiandrogenic properties among adolescents Contraception 2007; 76: 342-7.
19. Borges LE, Andrade R P, Aldrighi JM, et al. Efect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fuid-related symptoms in women with premenstrual disorders requesting contraception. Contraception 2006; 74: 446-50.
20. Apter D, Borsos A, Baumgartner W, et al. Efect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fuid-related symptoms. Eur J Contracept Reprod Health Care 2003; 8: 37-51.
21. Wiklund I, Holst J, Karlberg J. A new methodological approach to the evaluation of quality of life in postmenopausal women Maturitas 1992; 14: 211-24.